Capstan Medical Raises $110M for Robotic-Enabled Heart Valve SolutionCapstan Medical Raises $110M for Robotic-Enabled Heart Valve Solution

Capstan Medical has raised $110 million in a series C round to bring its robotic-enabled minimally invasive solutions to address heart valve disease to market.

This follows a $31.4 million round the Santa Cruz, CA-based company closed in August of 2023. The series C round was led by Eclipse, with participation from existing including Yu Galaxy and Intuitive Ventures, and new investment from Gideon Strategic Partners.

The new funding will give the company the opportunity to accelerate clinical trials; expand research and development, and scale operations.  

Capstan's minimally invasive solution seeks to overcome the limitations of current treatment options by bringing together novel heart valve implants and advanced catheter technology, fully enabled through a robotic platform, to treat a broader set of patients.

"Percutaneous intervention has the opportunity to dramatically increase the treatment options for the millions of people suffering from heart valve disease. At Capstan, we believe that our robotic platform with a full portfolio of implants can uniquely address the urgent needs of this underserved patient population," said Maggie Nixon, CEO of Capstan Medical. "We have pulled together the right people at the right time to make this happen and are energized by the incredible support of our investors." 

Related:FastWave Granted 7th Utility Patent